Roger Neil Sleigh

Title: Roger Neil Sleigh: Innovator in Cancer Treatment

Introduction

Roger Neil Sleigh is a notable inventor based in Dundee, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for proliferative disorders. His innovative work has led to the granting of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Roger Neil Sleigh holds a patent for a combination of a CDK inhibitor and CS-682 or a metabolite thereof. This invention includes several aspects: the first aspect relates to a combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. The second aspect involves a pharmaceutical product that combines these elements for simultaneous, sequential, or separate use in therapy. The third aspect outlines a method for treating a proliferative disorder by administering the CDK inhibitor and the specified compound to a subject.

Career Highlights

Roger is associated with Cyclacel Limited, a company focused on developing innovative cancer therapies. His work at Cyclacel has positioned him as a key player in the pharmaceutical industry, contributing to advancements in cancer treatment.

Collaborations

Roger has collaborated with notable colleagues, including Simon Richard Green and Simon Green. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in the field.

Conclusion

Roger Neil Sleigh's contributions to the pharmaceutical industry, particularly through his patent, demonstrate his commitment to improving cancer treatment. His work continues to inspire advancements in medical science and offers hope for patients facing proliferative disorders.